12th Apr 2016 07:17
LONDON (Alliance News) - Quantum Pharma PLC on Tuesday said its Colonis Pharma Ltd unit has received UK marketing approval for two new strengths of Vitamin D capsules from the Medicines & Healthcare products Regulatory Agency.
The 800 IU and 1,000 IU capsules are in both branded and generic versions, Quantum said, giving a total of four new licensed products.
"We are delighted to receive licences for these two new strengths of our Vitamin D range in both branded and generic presentations. Vitamin D deficiency is a growing market in which we are seeking to become a significant player through our commitment to developing a broad product range," said Andrew Scaife, Quantum's chief executive.
Quantum shares were untraded early Tuesday, having last traded at 56.25 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Quantum Pharma